SMOKING

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

H-J Aubin¹, A Bobak², J R Britton³, C Oncken⁴, C B Billing, Jr⁵, J Gong⁵, K E Williams⁵, K R Reeves⁵

¹ Hôpital Emile Roux, Assistance Publique-Hopitaux de Paris, Limeil-Brévannes; Centre d’Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, Paris; Assistance Publique-Hôpitaux de Paris; INSERM, U669, Paris, France
² Wandsworth Medical Centre, London, UK
³ University of Nottingham, Nottingham, UK
⁴ University of Connecticut Health Center, Farmington, Connecticut, USA
⁵ Pfizer Global Research and Development, Groton, Connecticut, USA

Dr H-J Aubin, Centre de Traitement des Addictions, Hôpital Emile Roux, F-94456 Limeil-Brévannes Cedex, France; henri-jean.aubin{at}erx.aphp.fr

Background: Varenicline, a new treatment for smoking cessation, has demonstrated significantly greater efficacy over placebo and sustained release bupropion (bupropion SR). A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal nicotine replacement therapy (NRT) for smoking cessation.

Methods: In this 52-week, open-label, randomised, multicentre, phase 3 trial conducted in Belgium, France, the Netherlands, UK and USA, participants were randomly assigned (1:1) to receive varenicline uptitrated to 1 mg twice daily for 12 weeks or transdermal NRT (21 mg/day reducing to 7 mg/day) for 10 weeks. Non-treatment follow-up continued to week 52. The primary outcome was the biochemically confirmed (exhaled carbon monoxide 10 ppm) self-reported continuous abstinence rate (CAR) for the last 4 weeks of the treatment period in participants who had taken at least one dose of treatment. Secondary outcomes included CAR from the last 4 weeks of treatment through weeks 24 and 52, and measures of craving, withdrawal and smoking satisfaction.

Results: A total of 376 and 370 participants assigned to varenicline and NRT, respectively, were eligible for analysis. The CAR for the last 4 weeks of treatment was significantly greater for varenicline (55.9%) than NRT (43.2%; OR 1.70, 95% CI 1.26 to 2.28, p<0.001). The week 52 CAR (NRT, weeks 8–52; varenicline, weeks 9–52) was 26.1% for varenicline and 20.3% for NRT (OR 1.40, 95% CI 0.99 to 1.99, p = 0.056). Varenicline significantly reduced craving (p<0.001), withdrawal symptoms (p<0.001) and smoking satisfaction (p<0.001) compared with NRT. The most frequent adverse event was nausea (varenicline, 37.2%; NRT, 9.7%).

Conclusions: The outcomes of this trial established that abstinence from smoking was greater and craving, withdrawal symptoms and smoking satisfaction were less at the end of treatment with varenicline than with transdermal NRT.

Trial registration number: NCT00143325.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Airwaves

Wisia Wedzicha
Thorax 2008 63: 663. [Extract] [Full Text] [PDF]

The place of varenicline in smoking cessation treatment

Paul Aveyard
Thorax 2008 63: 666-668. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Bolin, K., Wilson, K., Benhaddi, H., de Nigris, E., Marbaix, S., Mork, A.-C., Aubin, H.-J. (2009). Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. Eur J Public Health 19: 650-654 [Abstract] [Full Text]  
• Tonstad, S. (2009). Smoking cessation: how to advise the patient. Heart 95: 1635-1640 [Full Text]  
• Fagerstrom, K. O., Jimenez-Ruiz, C. A. (2008). Pharmacological treatments for tobacco dependence. ERR 17: 192-198 [Abstract] [Full Text]  
• Hays, J. T., Ebbert, J. O. (2008). Varenicline for Tobacco Dependence. NEJM 359: 2018-2024 [Full Text]  
• Aveyard, P. (2008). The place of varenicline in smoking cessation treatment. Thorax 63: 666-668 [Full Text]  
• Rose, J E (2008). Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field. Thorax 63: 751-752 [Full Text]  
• Hillman, T, Rajakulasingam, K, Bhowmik, A (2008). Clinically significant outcomes in smoking cessation. Thorax 63: 752-752 [Full Text]